Literature DB >> 18498420

Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions.

Brigette B Y Ma1, Edwin P Hui, Anthony T C Chan.   

Abstract

Systemic therapy is an integral part of the management of non-keratinizing nasopharyngeal carcinoma (NPC). The purposes of this review are to provide the latest results and future directions of clinical and translational research for this disease, and to illustrate how some of these new therapies have improved the treatment outcome for patients with NPC. Particular attention will be paid to the clinical application of chemotherapy in the adjunctive treatment of locoregionally advanced NPC, novel targeted drugs, Epstein-Barr virus-targeted vaccine therapies, and the use of plasma Epstein-Barr virus DNA as a biomarker for selecting patients for adjunctive therapies.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18498420     DOI： 10.1111/j.1349-7006.2008.00836.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN： 1347-9032            Impact factor:   6.716


  46 in total

1.  Reduced expression of polymeric immunoglobulin receptor (pIgR) in nasopharyngeal carcinoma and its correlation with prognosis.

Authors:  Xuanchang Qi; Xuechang Li; Xiuxia Sun
Journal:  Tumour Biol       Date:  2016-02-24

2.  Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines.

Authors:  Brigette B Y Ma; Vivian W Y Lui; Connie W C Hui; Cecilia P Y Lau; Chi-Hang Wong; Edwin P Hui; Margaret H Ng; S W Tsao; Yan Li; Anthony T C Chan
Journal:  Invest New Drugs       Date:  2012-11-11       Impact factor: 3.850

3.  Slug inhibition increases radiosensitivity of nasopharyngeal carcinoma cell line C666-1.

Authors:  Hongxia Yang; Gang Zhang; Xiaolin Che; Shudong Yu
Journal:  Exp Ther Med       Date:  2018-02-07       Impact factor: 2.447

4.  Phase II study of gemcitabine plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy.

Authors:  PeiJian Peng; XueQing Ou; Hai Liao; YuMeng Liu; SiYang Wang; ZhiBin Cheng; Zhong Lin
Journal:  Ther Adv Med Oncol       Date:  2016-03-11       Impact factor: 8.168

5.  Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma.

Authors:  Edwin Pun Hui; Vivian W Y Lui; Cesar S C Wong; Brigette B Y Ma; Cecilia P Y Lau; Crystal S F Cheung; Kakiu Ho; Suk-Hang Cheng; Margaret H L Ng; Anthony T C Chan
Journal:  Invest New Drugs       Date:  2010-05-15       Impact factor: 3.850

6.  Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma.

Authors:  Jianwei Zhang; Wenfeng Fang; Tao Qin; Yunpeng Yang; Shaodong Hong; Wenhua Liang; Yuxiang Ma; Hongyun Zhao; Yan Huang; Cong Xue; Peiyu Huang; Zhihuang Hu; Yuanyuan Zhao; Li Zhang
Journal:  Med Oncol       Date:  2015-02-22       Impact factor: 3.064

7.  The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines.

Authors:  Brigette B Y Ma; Vivian W Y Lui; Edwin P Hui; Cecilia P Y Lau; Kakiu Ho; Margaret H L Ng; S H Cheng; Sai-Wah Tsao; Anthony T C Chan
Journal:  Invest New Drugs       Date:  2009-05-27       Impact factor: 3.850

8.  Nasopharyngeal carcinoma: our experience.

Authors:  Carla d'Espiney Amaro; Pedro Montalvão; Pedro Henriques; Miguel Magalhães; João Olias
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-10-02       Impact factor: 2.503

9.  Sp1 is over-expressed in nasopharyngeal cancer and is a poor prognostic indicator for patients receiving radiotherapy.

Authors:  Jun Wang; Min Kang; Yu-Tao Qin; Zhu-Xin Wei; Jing-Jian Xiao; Ren-Sheng Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

10.  Identification of long non-coding RNA CCAT1 as an oncogene in nasopharyngeal carcinoma.

Authors:  Yameng Dong; Haozhan Yuan; Guangyu Jin
Journal:  Oncol Lett       Date:  2018-06-13       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.